Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts
Open Access
- 22 August 2022
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (11) , 754-759
Abstract
No abstract availableKeywords
Funding Information
- Janssen Pharmaceutica
- Bristol-Myers Squibb
- Merck
This publication has 24 references indexed in Scilit:
- Limiting the Daily Total Nucleated Cell Dose of Cryopreserved Peripheral Blood Stem Cell Products for Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact on Hematopoietic EngraftmentTransplantation and Cellular Therapy, 2012
- The effective use of plerixafor as a real‐time rescue strategy for patients poorly mobilizing autologous CD34+ cellsJournal of Clinical Apheresis, 2012
- How I treat patients who mobilize hematopoietic stem cells poorlyBlood, 2011
- Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilizationBone Marrow Transplantation, 2010
- Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphomaBone Marrow Transplantation, 2010
- Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experienceBone Marrow Transplantation, 2009
- AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use dataBone Marrow Transplantation, 2007
- Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphomaBone Marrow Transplantation, 2007
- Neutrophil Homeostasis: A New Role for Stromal Cell–Derived Factor-1Immunologic Research, 2005
- Poor Mobilization of Peripheral Blood Stem Cells is a Risk Factor for Worse Outcome in Lymphoma Patients Undergoing Autologous Stem Cell TransplantationLeukemia & Lymphoma, 2003